Latest Non-alcoholic fatty liver disease Stories
DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease
Researchers from The Netherlands found that snacking on high-fat and high-sugar foods was independently associated with abdominal fat and fatty liver (hepatic steatosis).
CHICAGO, May 6, 2014 /PRNewswire/ -- Research presented this week at Digestive Disease Week® (DDW) provides insight into the development and new treatments of diseases, such as nonalcoholic fatty
A UK study investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity.
Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD).
ReportsnReports.com offers "OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" 2014 market research report in
Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals
In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University-led team of researchers examined the metabolic breakdown that takes place in liver cells during late-stage cirrhosis and found clues that suggest new treatments to delay liver failure.